Skip to main content
Premium Trial:

Request an Annual Quote

RNAi Drug for Acute Hepatic Porphyria

The US Food and Drug Administration has approved the RNA interference drug givosiran (Alnylam Pharmaceuticals' Givlaari) to treat acute hepatic porphyria in adults, according to the agency.

Acute hepatic porphyria is an inherited disorder in which porphyrin accumulates during heme production and can lead to pain, paralysis, seizures and other symptoms, as MedPage Today reports. According to Alnylam, there are four types of acute hepatic porphyria, each of which stem from genetic alterations affecting enzymes in the liver's heme biosynthesis pathway. Givosiran is an RNAi drug that targets aminolevulinic acid synthase 1 mRNA to reduce its levels and the levels of toxins associated with attacks.

"Prior to today's approval, treatment options have only provided partial relief from the intense unremitting pain that characterizes these attacks," Richard Pazdur, the director of FDA's Oncology Center of Excellence and acting director of the Office of Oncologic Diseases says in a statement. "The drug approved today can treat this disease by helping to reduce the number of attacks that disrupt the lives of patients."

Reuters adds that the drug will cost about $575,000 per year.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.